W
Walter Berger
Researcher at Medical University of Vienna
Publications - 396
Citations - 16667
Walter Berger is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Cancer & Cell culture. The author has an hindex of 63, co-authored 359 publications receiving 14045 citations. Previous affiliations of Walter Berger include University of Vienna & Université libre de Bruxelles.
Papers
More filters
Journal ArticleDOI
Computed determination of the in vitro optimal chemocombinations of sphaeropsidin A with chemotherapeutic agents to combat melanomas
Aude Ingels,Carina Dinhof,Abhishek D. Garg,Lucia Maddau,Marco Masi,Antonio Evidente,Walter Berger,Bieke Dejaegher,Véronique Mathieu +8 more
TL;DR: Combining the Na+/K+/2Cl− cotransporter and/or anion exchanger inhibitor Sph A with chemotherapeutic agents could improve the therapeutic benefits of conventional chemotherapies against advanced melanomas, particularly because Sph A exerts cytotoxic effects regardless of the genetic BRAF and NRAS status.
Journal ArticleDOI
Ex-vivo analysis of quantitative 5-ALA fluorescence intensity in diffusely infiltrating gliomas using a handheld spectroscopic probe: Correlation with histopathology, proliferation and microvascular density.
Mauricio Martínez-Moreno,Barbara Kiesel,Adelheid Woehrer,Mario Mischkulnig,Julia Furtner,Gerald Timelthaler,Walter Berger,Engelbert Knosp,Johannes A. Hainfellner,Stefan Wolfsberger,Georg Widhalm +10 more
TL;DR: The data indicate that handheld spectroscopic probes are capable visualizing intratumoral glioma heterogeneity by objective assessment of fluorescence and will thus optimize in future gliomas surgery.
Journal ArticleDOI
Interim analysis of a real-world precision medicine platform for molecular profiling of metastatic or advanced cancers: MONDTI
Markus Kieler,Matthias Unseld,Daniela Bianconi,Fredrik Waneck,Robert M. Mader,Fritz Wrba,Thorsten Fuereder,Christine Marosi,Markus Raderer,Philipp B. Staber,Walter Berger,Maria Sibilia,Stephan Polterauer,Leonhard Müllauer,Matthias Preusser,Christoph C. Zielinski,Gerald W. Prager +16 more
TL;DR: The results reveal that the open concept for all solid tumours characterised for molecular profile and immunotherapy could not only match individualised treatment concepts at a high rate but also underscores the challenges encountered when offering molecularly matched therapies to a patient population with an advanced stage cancer.
Journal ArticleDOI
The First Anticancer Tris(pyrazolyl)borate Molybdenum(IV) Complexes: Tested in Vitro and in Vivo—A Comparison of O,O‐, S,O‐, and N,N‐Chelate Effects
Iker Berasaluce,Klaudia Cseh,Alexander Roller,Michaela Hejl,Petra Heffeter,Petra Heffeter,Walter Berger,Walter Berger,Michael A. Jakupec,Wolfgang Kandioller,Michael S. Malarek,Bernhard K. Keppler +11 more
TL;DR: The synthesis, characterization and biological activity of molybdenum(IV) complexes containing Trofimenko's scorpionato ligand, hydrotris(3‐isopropylpyrazolyl)borate (TpiPr), in addition to varying biologically active as well as other conventional ligands is described.
Journal ArticleDOI
Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations.
Tamás Garay,Eszter Molnár,Éva Juhász,Viktoria Laszlo,Tamás Barbai,Judit Dobos,Karin Schelch,Christine Pirker,Michael Grusch,Walter Berger,József Tímár,Balázs Hegedűs,Balázs Hegedűs +12 more
TL;DR: It is demonstrated that the oncogenic mutations in melanoma have a profound impact on the motogenic effect of the activation of growth factor receptor signaling.